#### RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

#### Inter-laboratory variability of the standardized ETP-based APC resistance assay (PB0386)

Morimont, Laure; Maloteau, Vincent; Devel, Philippe; Dogné, Jean-Michel; Bouvy, Céline; Douxfils, Jonathan

Publication date: 2020

#### Link to publication

Citation for pulished version (HARVARD):

Morimont, L, Maloteau, V, Devel, P, Dogné, J-M, Bouvy, C & Douxfils, J 2020, 'Inter-laboratory variability of the standardized ETP-based APC resistance assay (PB0386)', ISTH 2020 virtual congress: July 12-14, 2020, 12/07/20 - 14/07/20.

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
  You may freely distribute the URL identifying the publication in the public portal?

#### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 03. Jul. 2025



# Inter-laboratory variability of the standardized ETP-based APC resistance assay (PB0386)

L. MORIMONT <sup>1,2</sup>, V. Maloteau <sup>2</sup>, P. Devel<sup>2</sup>, J-M. Dogné<sup>2</sup>, C. Bouvy<sup>1</sup>, J. Douxfils <sup>1,2</sup>



#### INTRODUCTION

- Risk minimization measures need to be implemented to reduce the thrombotic risk associated with the use of combined oral contraceptives (COC). However, there is controversy on how to assess the risk at an acceptable cost for the society.
- Despite regulatory bodies recommend the assessment of the ETPbased activated protein C (APC) resistance during the development of steroid contraceptives; results are not comparable between studies due to lack of validation and standardization.
- To overcome this issue, our group recently validated and standardized this assay.
- However, further investigations are needed before a wide implementation of this method.

#### AIM

To assess the inter-laboratory variability of the validated ETP-based APC resistance assay.

# **METHOD**


- Analyses were performed on 3 Calibrated Automated Thrombogram (CAT) with Thrombinoscope software (version 5.0 for  $CAT_{182}$ ; version 2.0 for  $CAT_3$ ) and by 3 different operators.
- Dose-response curves (n=3) were performed on each device to defined the amount of APC, leading to
- o (a) 90% of inhibition of the ETP on an in-house reference plasma,
- (b) the corresponding inhibition % on a commercial reference plasma.
- Quality controls (n=3) and a subset of real-life samples (n=11) were tested on each equipment.
- All measurements were performed in duplicate.

### **RESULTS**

- Dose-response curves did not show any significant differences between CAT<sub>1</sub> and CAT<sub>2</sub> (Dunn's multiple comparison test; p-value > 0.9999) on both, commercial and in-house reference plasma Table/Figure 1.
- An APC concentration of 217 mU/mL led to 90% of inhibition of the ETP on the homemade reference plasma and 68% of inhibition on the commercial reference plasma Table/Figure 1.

FIGURE 1: Total variability between CAT<sub>1</sub> and CAT<sub>2</sub> The red dotted line represents the reference range of in-house reference plasma (90±2.5%) and the blue dotted line represents the reference range of commercial reference plasma (68±8%). The green dotted line represents the defined concentration of APC (217 mU/mL) to fit the reference ranges

**TABLE 1:** Inhibition percentage at 6 concentration levels of APC with in-house reference plasma and commercial reference plasma on CAT<sub>1</sub> and CAT<sub>2</sub>. Inhibition % in blue\* are



	U	<b>5</b> 0	100	150	200	250	300
			AP	C (ml	J/mL)		
-	In house			-	Comme	rcial ref	ference
	plasma	$(R^2 0.9)$	997)		plasma	$(R^2 0.99)$	933)

	In-house reference plasma			Commercial reference plasma		
[APC]	Inhibition %		p-value	Inhibition %		p-value
	CAT 1	CAT 2	p-value	CAT1	CAT2	p-value
	26,69*	52,05	>0.9999	14,65	27,48	>0.9999
65 mU/mL	28,71*	56,13		17,18	31,35	
	44,24	59,57		25,53	24,7	
	64,77	70,39	>0.9999	38,94	40,71	>0.9999
100 mU/mL	mL 62,63	64,34		37,51	47,3	
	69,72	68,21		44,32	45,7	
	73,9	80,1	>0.9999	46,84	52,14	>0.9999
130 mU/mL	68,15	76,11		44,37	56,42	
	80,23	77,84		52,77	54,82	
	90,27	89,45	>0.9999	65,05	67,54	>0.9999
200 mU/mL	87,92	81,62		68,86	71,88	
	92,09	88,72		71,27	69,99	
	95,25	93,42	>0.9999	74,02	74,4	
250 mU/mL	91,58	89,48		72,16	78,83	>0.9999
	95,47	92,47		79,06	74,66	
	97,19	95,87	>0.9999	78,86	79,58	>0.9999
300 mU/mL	96,13	82,89*		83,06	85,8	
	96,55	95,08		83,69	79,92	
Defined concentration of APC (95%CI): <b>217 mU/mL</b> [197 mU/mL-249 mU/mL]						

•	A mean deviation of 7.83% was
	observed when comparing samples
	tested on both CAT device at the
	defined APC concentration of 217
	mU/mL (►Table 2).

TARIF 2: Inhihitic	an nercentage			
<b>TABLE 2</b> : Inhibition percentage and absolute difference		Inhibit	Difference	
between CAT1 and CAT2.		CAT 1	CAT 2	Difference
	In-house ref plasma	88,66%	94,56%	5,90%
	Commercial ref plasma	64,81%	74,36%	9,55%
	QC Low	98,19%	100,16%	1,96%
	QC Norm	31,22%	44,17%	12,95%
	QC High	7,18%	9,70%	2,52%
	S1	91,99%	96,34%	4,36%
	S2	77,01%	81,54%	4,53%
	<b>S</b> 3	78,53%	86,07%	7,54%
	S4	64,74%	74,16%	9,42%
	<b>S</b> 5	56,94%	64,92%	7,97%
	<b>S</b> 6	68,84%	79,33%	10,49%
	S7	69,03%	76,53%	7,49%
	S8	69,02%	76,42%	7,40%
	<b>S</b> 9	46,88%	60,55%	13,67%
	S10	61,99%	71,36%	9,37%
	S11	40,69%	50,90%	10,21%
		Mean d	7,83%	

software of the CAT<sub>3</sub> modifications must be performed to ensure the transferability of the methodology. This is due to important background noise which limits performance of this older version of the CAT<sub>3</sub> at low ETP-values.

# CONCLUSIONS

- These results demonstrate the transferability of the validated ETP-based APC resistance test between CATs using the same software version.
- In order to confirm the reliability of the results obtained with this validated method, its implementation in other centre is essential.
- The conduct of a larger multi-centre study should therefore be performed before implementing this technique in the routine setting.

### REFERENCES

- $^{1}$  Guideline on clinical investigation of steroid contraceptives in women -EMEA/CPMP/EWP/519/98 Rev 1.
- <sup>2</sup> Morimont, L., et al. (2020). "Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance." J Thromb Haemost **18**(4): 895-904.
- <sup>3</sup> Douxfils, J., et al. (2020). "Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need." Clin Chem Lab Med **58**(2): 294-305.

# **ACKNOWLEDGEMENTS**

This study was financed by QUALIblood s.a and the brussels-Wallonia federation (convention no. 8031).

## **CONTACT INFORMATION**

Email: laure.morimont@qualiblood.eu

Tel: 32 (0)81 72 42 92

<sup>&</sup>lt;sup>1</sup> QUALIblood s.a., Namur Belgium

<sup>&</sup>lt;sup>2</sup> University of Namur, Department of Pharmacy, Namur Thrombosis and Hemostasis center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium